Add to ORKGO.H.A. are the most common form of treatment of Type2 D.M. worldwide. When used judiciously they are important agents in the management of the most common form of diabetes. For economic, logistic and general effectiveness, oral agents are a dependable means of treating a large population of diabetics worldwide when used correctly
Diabetes, a chronic progressive life-long metabolic disorder, is characterised by hyperglycaemia, wh...
The aim of this study was to evaluate safety and efficacy of oral hypoglycemic agents in obese Type-...
The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyper...
The number of patients with type 2 diabetes mellitus (DM2) is steadily increasing. According to Diab...
peer reviewedType 2 diabetes is a heterogeneous disease resulting from a dynamic interaction between...
Various kinds of oral hypoglycemic agents (OHA) are currently available for the treatment of type 2 ...
Background: Diabetes mellitus type 2 is a chronic disease that may be due to insulin deficiency and ...
Oral hypoglycemic drug therapy has successfully been used for controlling type-2 Diabetes...
Diabetes mellitus (DM) is a chronic, progressive, and multifaceted illness resulting in significant ...
Type 2 diabetes mellitus (formerly named non-insulin-dependent diabetes mellitus or NIDDM) is a hete...
Type 2 diabetes mellitus (T2DM) is caused by insulin resistance and characterized by progressive pan...
There is currently no cure for diabetes mellitus (DM). Irrespective of whether type I or type II dia...
Šećerna bolest je učestala metabolička bolest koja zahvaća metabolizam ugljikohidrata, masti i prote...
Type 2 diabetes mellitus (T2DM) is a chronic progressive disease characterized by chronic hyperglyce...
Type 2 diabetes mellitus (T2DM) is a progressive disease characterised by beta cell dysfunction and ...
Diabetes, a chronic progressive life-long metabolic disorder, is characterised by hyperglycaemia, wh...
The aim of this study was to evaluate safety and efficacy of oral hypoglycemic agents in obese Type-...
The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyper...
The number of patients with type 2 diabetes mellitus (DM2) is steadily increasing. According to Diab...
peer reviewedType 2 diabetes is a heterogeneous disease resulting from a dynamic interaction between...
Various kinds of oral hypoglycemic agents (OHA) are currently available for the treatment of type 2 ...
Background: Diabetes mellitus type 2 is a chronic disease that may be due to insulin deficiency and ...
Oral hypoglycemic drug therapy has successfully been used for controlling type-2 Diabetes...
Diabetes mellitus (DM) is a chronic, progressive, and multifaceted illness resulting in significant ...
Type 2 diabetes mellitus (formerly named non-insulin-dependent diabetes mellitus or NIDDM) is a hete...
Type 2 diabetes mellitus (T2DM) is caused by insulin resistance and characterized by progressive pan...
There is currently no cure for diabetes mellitus (DM). Irrespective of whether type I or type II dia...
Šećerna bolest je učestala metabolička bolest koja zahvaća metabolizam ugljikohidrata, masti i prote...
Type 2 diabetes mellitus (T2DM) is a chronic progressive disease characterized by chronic hyperglyce...
Type 2 diabetes mellitus (T2DM) is a progressive disease characterised by beta cell dysfunction and ...
Diabetes, a chronic progressive life-long metabolic disorder, is characterised by hyperglycaemia, wh...
The aim of this study was to evaluate safety and efficacy of oral hypoglycemic agents in obese Type-...
The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyper...